SCHEMBL6315554

SCHEMBL6315554

CC(C)CCNC(=O)c1c(-c2ccc(Br)s2)noc1N

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 3/20 0.49
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA4 P22748 2/20 0.41
CA7 P43166 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.39
HPGD P15428 4/20 0.38
GAA P10253 3/20 0.38
NPSR1 Q6W5P4 3/20 0.38
KDM4E B2RXH2 3/20 0.38
ALDH1A1 P00352 3/20 0.38
RECQL P46063 2/20 0.38
USP2 O75604 2/20 0.38
MAPT P10636 2/20 0.38
BLM P54132 2/20 0.38
HSD17B10 Q99714 2/20 0.38
THRB P10828 1/20 0.38
ALOX15 P16050 1/20 0.38
TSHR P16473 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6316101 0.89 CA1 (0.42) RXFP1CA1CA2CA4CA7
SCHEMBL6323087 0.89 RAB9A (0.44) RXFP1CA1CA2CA4CA7
SCHEMBL6616829 0.88 RXFP1 (0.45) RXFP1CA1CA2CA4CA7
SCHEMBL6317494 0.88 RAB9A (0.43) RXFP1CA1CA2CA4CA7
SCHEMBL6318990 0.87 CA1 (0.41) RXFP1CA1CA2CA4CA7
SCHEMBL6317773 0.87 CA1 (0.55) RXFP1CA1CA2CA4CA7
SCHEMBL6324432 0.86 EPHX2 (0.48) RXFP1CA1CA2CA4CA7
SCHEMBL6324099 0.86 CA1 (0.41) RXFP1CA1CA2CA4CA7
SCHEMBL6323150 0.85 RXFP1 (0.43) RXFP1CA1CA2CA4CA7
SCHEMBL885523 0.84 CA1 (0.39) RXFP1CA1CA2CA4CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 RXFP1 4558/4885CA1 2406/4885CA2 2764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.